Skip to main content

Advertisement

Log in

Primary glial tumor patients treated by combining cis-platin and etoposide

  • Clinical Study
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Summary

Thirty eight patients with malignant gliomas (27 GBM and 11 AA) were treated with up to 7 cycles of CDDP + VP16 every month after surgery. Chemotherapy was planned as two cycles before and 5 cycles after radiation (42 Gy) using a three times daily fractionation schedule. No severe toxicity was observed. The object of our study was to investigate the antitumor effectiveness by combining CDDP plus VP16 against primary malignant glial tumors. The time to tumor progression (TTP) and survival time (ST) of the GBM patients in the present study were 38.5 and 68,5 weeks respectively. The TTP of the AA patients was 73 weeks and the ST was not calculated as most patients are still alive. By the 18th. month after surgery, 38% of GBM and 74% of AA patients treated with (CDDP + VP16) are still alive. This study demonstrates that the combination of CDDP and VP16 is effective in patients with malignant gliomas.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Dodin P, Sanders C, Georges P and Kenis Y:In vitro chemosensitivity of brain tumors to cisplatin and its analogues, iproplatin and carboplatin. Cancer Chemother Pharmacol 22: 80–82, 1988

    Google Scholar 

  2. Prestayko AW, D'Aqust JC, Iessel BF: Cis-platin. Cancer Treat Rev 6: 17–39, 1979

    CAS  PubMed  Google Scholar 

  3. Khan AB, D'Souza BJ, Wharam M, Champion Laa, Sinks LF, Woo SY, McCullough DC, Leventhal BG: Cisplatin in therapy in recurrent childhood brain tumors. Cancer Treat Rep 66: 2013, 1982

    CAS  PubMed  Google Scholar 

  4. Bertolone S, Baum E, Krivit W and Hammond D: A phase II study of cisplatin therapy in recurrent childhood brain tumor. J of Neuro-Oncol 7: 5–11, 1989

    CAS  Google Scholar 

  5. Sexauer CL, Khan A, Burger PC, Krischer JP, Eys J, Vats T, Ragato AH: Cisplatin in recurrent pediatric brain tumors. A POG Phase II study. Cancer 56: 1497–1501, 1985

    CAS  PubMed  Google Scholar 

  6. Graig E, Stephen B, Howel B, Felthouse D, Woliver T, Andrews A, Markbamn M and Murphy M: High-dose Cisplatin with sodium Thiosulfate protection. J Clin Oncol 3: 237–244, 1985

    Google Scholar 

  7. Feun LG, Lee YY, Wallace S: New drugs and new delivery techniques. Prog Exp Tumor Res 29: 131, 139, 1985

    CAS  PubMed  Google Scholar 

  8. Steward DJ, O'Bryan RM, Al-Sarraf M: Phase II study of cisplatin in recurrent astrocytomas in adults: a Southwest Oncology Group Study. J Neurooncol 1: 145, 147, 1983

    Google Scholar 

  9. Einhorn LH and Williams SD: The role of cisplatinum in solid tumor therapy N Engl: J Med 300: 291–294, 1979

    Google Scholar 

  10. Burchenal JH, Lokys L: Tumor therapy. In: Prestaiko AW. Cooke ST (ed): Carter SK: Cisplatin: current status and new developments. NY Academic Press 1980

  11. Kobayashi T, Yoshida J, Ishiyama J, Noda S, Kito A, Kida Y: Combination chemotherapy with cisplatin and etoposide for malignant intracranial germ-tumor. J Neurosurg 70: 676–681, 1989

    CAS  PubMed  Google Scholar 

  12. Tirelli U, D'Incalci M, Canetta R: Etoposide in malignant brain tumors: A Phase II study: J Clin Oncol 2: 432–437, 1984

    CAS  PubMed  Google Scholar 

  13. Steward DJ, Richard MT, Hugenholtz H: Penetration of VP16 into human intracerebral and extracerebral tumors. J Neuro Oncol 2: 133–140, 1984

    Google Scholar 

  14. Nelson DF, Schoenfeld D, Weinstein AS: A randomized comparison of misonidazole sensitizer chemotherapy plus BCNU for treatment of malignant glioma after surgery; preliminary results of an EORTC study. Int J Radiat Oncol Biol Phys 9: 1143–1151, 1983

    CAS  PubMed  Google Scholar 

  15. Zupi G, Greco C, Sacchi A, Calabresi F: Etoposide prior to cis-diamminedichloroplatinum in combination chemotherapyin vitro andin vivo studies. Eur J Cancer Clin Oncol 12: 1501–1506, 1895

    Google Scholar 

  16. Steward DJ, Leavens M, Feun M, Luna M, Bonura J, Caprioloi R, Loo T, Benjamin S: Human central nervous system distribution of cis-platin and use as radiosensitizer in malignant brain tumors. Cumuliforme-results of phase II study. Int J Radiot Oncol Biol Phys 8: 1787–1794, 1982

    Google Scholar 

  17. Kornblith P and Walker M: Chemotherapy for malignant gliomas. J Neurosurg 68: 1–17, 1988

    CAS  PubMed  Google Scholar 

  18. Edwards MS, Levin VA and Wilson CB: Brain tumor chemotherapy: An evaluation of agents in current use for phase II and III trials. Cancer Treat Rep 64: 1179–1205, 1980

    CAS  PubMed  Google Scholar 

  19. Levin VA, Wilson CB, Davis R, Wara WM, Pischer TR, Irwin L: A phase III comparison of BCNU, hydroxyurea and radiation therapy to BCNU and radiation therapy for treatment of primary malignant gliomas. J Neurosurg 51: 526–532, 1979

    CAS  PubMed  Google Scholar 

  20. Krauseneck P and Mertens HG: Results of chemotherapy of malignant brain tumors in adults. In therapy of malignant brain tumors. Ed by Kurt Jellinger Springer-Verlag Wien New York 1987

    Google Scholar 

  21. Broggi G and Franzini A: Value of serial stereotactic biopsies and impedance monitoring in the treatment of deep brain tumors. J Neurol Neurosurg Psychiatry 44: 397–401, 1981

    CAS  PubMed  Google Scholar 

  22. Hoshino T: A commentary on the biology and growth kinetics of low grade and high grade gliomas. J Neurosurg 61: 895–900, 1984

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Boiardi, A., Silvani, A., Milanesi, I. et al. Primary glial tumor patients treated by combining cis-platin and etoposide. J Neuro-Oncol 11, 165–170 (1991). https://doi.org/10.1007/BF02390176

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02390176

Key words

Navigation